Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?

BACKGROUND: The 2019 novel coronavirus disease (COVID-19) causes for unresolved reasons acute respiratory distress syndrome in vulnerable individuals. There is a need to identify key pathogenic molecules in COVID-19-associated inflammation attainable to target with existing therapeutic compounds. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Andersson, Ulf, Ottestad, William, Tracey, Kevin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203545/
https://www.ncbi.nlm.nih.gov/pubmed/32380958
http://dx.doi.org/10.1186/s10020-020-00172-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203545/
https://www.ncbi.nlm.nih.gov/pubmed/32380958
http://dx.doi.org/10.1186/s10020-020-00172-4

Ejemplares similares